Healthcare provider profile · identity verified

Jose A Pares, MD

General Practice · CLERMONT, FL · NPI 1912115445

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	319	121
Rosuvastatin Calcium	Rosuvastatin Calcium	300	115
Lisinopril	Lisinopril	270	94
Amlodipine Besylate	Amlodipine Besylate	237	88
Losartan Potassium	Losartan Potassium	230	91
Metformin Hcl	Metformin Hcl	225	84
Levothyroxine Sodium	Levothyroxine Sodium	220	72
Vitamin D2	Ergocalciferol (Vitamin D2)	160	71
Glipizide	Glipizide	134	44
Metoprolol Succinate	Metoprolol Succinate	118	50
Gabapentin	Gabapentin	117	48
Pravastatin Sodium	Pravastatin Sodium	110	41
Azithromycin	Azithromycin	108	85
Carvedilol	Carvedilol	95	35
Pantoprazole Sodium	Pantoprazole Sodium	95	39
Trazodone Hcl	Trazodone Hcl	93	38
Hydrochlorothiazide	Hydrochlorothiazide	90	38
Omeprazole	Omeprazole	88	42
Furosemide	Furosemide	86	43
Tamsulosin Hcl	Tamsulosin Hcl	77	33
Alendronate Sodium	Alendronate Sodium	72	32
Albuterol Sulfate Hfa	Albuterol Sulfate	71	33
Montelukast Sodium	Montelukast Sodium	69	31
Diclofenac Sodium	Diclofenac Sodium	63	36
Dexamethasone	Dexamethasone	61	46
Fluticasone Propionate	Fluticasone Propionate	60	34
Famotidine	Famotidine	59	25
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	58	28
Glimepiride	Glimepiride	57	18
Metoprolol Tartrate	Metoprolol Tartrate	55	26
Ibuprofen	Ibuprofen	54	25
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	52	16
Finasteride	Finasteride	50	21
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	49	40
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	48	36
Buspirone Hcl	Buspirone Hcl	48	31
Clopidogrel	Clopidogrel Bisulfate	48	19
Prednisone	Prednisone	44	17
Ciprofloxacin Hcl	Ciprofloxacin Hcl	42	37
Lovastatin	Lovastatin	37	12
Sildenafil Citrate	Sildenafil Citrate	37	suppressed
Farxiga	Dapagliflozin Propanediol	36	16
Baclofen	Baclofen	35	18
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	34	24
Meclizine Hcl	Meclizine Hcl	34	18
Spironolactone	Spironolactone	34	17
Atenolol	Atenolol	33	suppressed
Nitroglycerin	Nitroglycerin	33	13
Amoxicillin	Amoxicillin	32	25
Meloxicam	Meloxicam	32	17
Sertraline Hcl	Sertraline Hcl	32	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	31	11
Simvastatin	Simvastatin	31	14
Telmisartan	Telmisartan	31	11
Memantine Hcl	Memantine Hcl	30	11
Olmesartan Medoxomil	Olmesartan Medoxomil	30	11
Oxybutynin Chloride	Oxybutynin Chloride	30	11
Eliquis	Apixaban	29	13
Pioglitazone Hcl	Pioglitazone Hcl	29	12
Valsartan	Valsartan	29	12
Celecoxib	Celecoxib	28	13
Duloxetine Hcl	Duloxetine Hcl	28	suppressed
Januvia	Sitagliptin Phosphate	28	suppressed
Latanoprost	Latanoprost	28	suppressed
Hydralazine Hcl	Hydralazine Hcl	27	13
Warfarin Sodium	Warfarin Sodium	27	14
Triamcinolone Acetonide	Triamcinolone Acetonide	26	12
Clonidine Hcl	Clonidine Hcl	25	suppressed
Jardiance	Empagliflozin	25	11
Sucralfate	Sucralfate	25	13
Naproxen	Naproxen	24	suppressed
Ozempic	Semaglutide	23	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	23	suppressed
Ropinirole Hcl	Ropinirole Hcl	22	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	21	suppressed
Enalapril Maleate	Enalapril Maleate	21	suppressed
Tizanidine Hcl	Tizanidine Hcl	21	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	20	11
Nifedipine Er	Nifedipine	20	suppressed
Ampicillin Trihydrate	Ampicillin Trihydrate	19	14
Brimonidine Tartrate	Brimonidine Tartrate	19	suppressed
Cephalexin	Cephalexin	19	16
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	19	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	17	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	17	suppressed
Neomycin-Polymyxin-Hc	Neomycin/Polymyxin B/Hydrocort	17	12
Neomycin-Polymyxin-Hydrocort	Neomycin/Polymyxin B/Hydrocort	17	15
Potassium Chloride	Potassium Chloride	17	suppressed
Synthroid	Levothyroxine Sodium	17	suppressed
Propranolol Hcl	Propranolol Hcl	16	suppressed
Tobramycin-Dexamethasone	Tobramycin/Dexamethasone	16	15
Dicyclomine Hcl	Dicyclomine Hcl	15	suppressed
Ezetimibe	Ezetimibe	15	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Megestrol Acetate	Megestrol Acetate	15	suppressed
Mupirocin	Mupirocin	15	14
Novolog	Insulin Aspart	15	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	14	suppressed
Chlorthalidone	Chlorthalidone	14	suppressed
Tramadol Hcl	Tramadol Hcl	14	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	14	suppressed
Acyclovir	Acyclovir	13	suppressed
Allopurinol	Allopurinol	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	12	suppressed
Metronidazole	Metronidazole	12	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	12	suppressed
Torsemide	Torsemide	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Citalopram Hbr	Citalopram Hydrobromide	11	suppressed
Cyproheptadine Hcl	Cyproheptadine Hcl	11	suppressed
Linzess	Linaclotide	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Nebivolol Hcl	Nebivolol Hcl	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed
Timolol Maleate	Timolol Maleate	11	suppressed
Trulicity	Dulaglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error